RSV

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

The world's first maternal vaccine against RSV in neonates and infants was approved in August. This brief slide show highlights the clinical trials that made history.

The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.

Delivering 3 vaccines to older adults is going to be a challenge this fall, says Dr William Schaffner.

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.

Medical director of the NFID William Schaffner, MD, discusses the research behind the FDA's decision to approve the first-ever RSV vaccine.

Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.

Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."

The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.

Onset of the 2022-2023 RSV season and its end were closer to historical patterns but atypical circulation may continue, say researchers writing in MMWR.